New Orleans Sign Advertising Voodoo
What I learnt at the recent AACR annual meeting in New Orleans is that cancer immunotherapy studies are requiring industry to think differently about clinical trial design.
As we move into combination trials of novel/novel combinations, how do we efficiently work out not only that each drug is safe, but in what patients they are likely to be most effective?
Readers who listened to the recent Novel Targets Podcast, “Of Mice and Men” will hear about some of the challenges associated with mouse models and how decisions are made moving into the clinic.
What I learnt from the podcast (and I hope you did too) is that if you are doing an immunotherapy trial in patients, the type of mouse model can really matter when it comes to interpretation of the preclinical data.
In response to a subscriber request, today’s post is about some of the statistical challenges in designing combination immunotherapy trials. To many, statistics is like voodoo, so this post does not go into any maths!
Subscribers can login to read more or you can purchase access by clicking on the blue button below.
New Orleans – Tuesday is the last full day of the 2016 annual meeting of the American Association for Cancer Research (AACR), and the last day of our #AACR16 rolling blog posts.
What struck me at this meeting has been the explosion in cancer immunotherapy research. It’s worth remembering that where we are today is the result of pioneering work done over the last 15 years by researchers, many of whom struggled for funding and recognition as they laid the foundation for where we are today.
Tomorrow, the Vice President of the United States, Joe Biden, will fly in to address the closing plenary session of the meeting. Mr Biden’s remarks will be live streamed by AACR (link to information).
There’s a lot happening at AACR today and tomorrow; and as conference die-hards we’ll be here to the end in order to capture some really interesting data that’s on the program.
Subscribers can login to read our AACR Day 4 commentary or you can purchase access in the blue box below.
New Orleans – here at the annual meeting of the American Association for Cancer Research (AACR), the emphasis has shifted from yesterday’s education program to the start of the scientific programme.
If you didn’t make it to the Cell Press/Nanostring, “What’s Next: Bit Topics in Cancer Immunology” event yesterday evening at the Bourbon Orleans hotel in the heart of the French Quarter, you missed a great unofficial AACR16 event that featured a panel of leading experts:
- Aviv Regev, PhD (Broad Institute of MIT and Harvard)
- Tom Gajewski, MD, PhD (University of Chicago)
- Dan Chen, MD, PhD (Genentech)
- Pam Sharma, MD, PhD (University of Texas MD Anderson Cancer Center)
- Michel Sadelain, MD, PhD (Memorial Sloan Kettering Cancer Center)
- Jerome Galon, PhD (INSERM)
- Ira Mellman, PhD (Genentech)
- Catherine Wu, MD (Dana Farber Cancer Institute)
Throughout the day, schedule permitting, we’ll be posting top-line commentary from the sessions we’ve been in.
You can also catch up with the commentary from the Day 1 Live Blog, which has several updates from yesterday (Link).
Subscribers can login below or you can purchase access by clicking on the blue icon.
New Orleans – the annual meeting of the American Association for Cancer Research (AACR) starts in earnest today with a full program of educational sessions presented by leading experts in different fields.
There’s a lot going on at AACR, with many sessions in parallel, so always remember the “law of two feet” – if the session you are in isn’t interesting, what you expected or isn’t meeting your needs – get up and go to another one!
Starting today and through Tuesday will be posting a daily blog with commentary around the sessions we attend and the people we speak to. It won’t be real-time, but to the extent possible we’ll be providing updates during the day.
It kills us to do semi-live posts from conferences, but they’re popular with subscribers, many of whom enjoy reading top-line commentary during the meeting, then our in-depth pieces later.
If you’d like to join the club of readers who enjoy access to our content, much of which by definition is exclusive – we don’t think anybody else does what we do or talks to as many thought leaders….
The good news is that a quarterly subscription will also cover you for ASCO 2016 in Chicago. If you’d like to support our conference coverage, you can purchase access below. Subscribers can login to read more.
New Orleans Jazz
Most of the abstracts for the 2016 annual meeting of the American Association for Cancer Research (Twitter #AACR16) in New Orleans are now available online, which raises the intriguing question:
What are the top 10 abstracts at AACR 2016?
If you’re a subscriber, take a moment to think which ones would be on your list, BEFORE you read this post.
Rather than give chapter and verse on a long raft of abstracts, in this second preview post I’ve chosen to focus on a few interesting, intriguing or important issues. Clearly, everyone will have their own way of defining a top 10 list, never mind choosing them! I do hope this starts a debate in your group, it’s always cool discussing science, after all. Which ones would you choose and why?
What I wanted to do was highlight some of the critical scientific or clinical questions that I have written down in my little black book over the last year or so for which we need solid answers in order to move our understanding of the cancer research along. That list is very long and always seems to be getting longer! The good news is that we may have answers to some of them at AACR next month.
Here goes, in no particular order…
Subscribers can login to read more or you can purchase access below: